MMED Trading Analysis - 11/06/2026 05:36 PM — TRU-SENTIMENT

MMED (MiniMed Group Inc. Common Stock) at $16.70. True Sentiment Bullish, delta 40-60 call 66% / put 34%, call $155,050 vs put $81,190. RSI 43.4.

TRU-SENTIMENT · DeltaNeutral

MMED Trading Analysis - 11/06/2026 05:36 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

MMED (MiniMed Group Inc. Common Stock) at $16.70. True Sentiment Bullish, delta 40-60 call 66% / put 34%, call $155,050 vs put $81,190. RSI 43.4.

Symbol
MMED
Price
$16.70
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-11-06 17:36:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options):

Options flow (Delta 40-60 only): Call Dollar Vol 155,050.00; Put Dollar Vol 81,190.00; Total 236,240.00. Call Pct 65.60, Put Pct 34.40. Sentiment: Bullish.

Call contracts 1,111 vs Put 185 — strong call-side conviction. But spread engine notes divergence: "Options sentiment is Bullish but technicals are Bearish." Pure directional positioning suggests near-term bounce expectation unavailable in price yet.

Note: Options flow shows bullish delta-weighted call buying despite daily chart breakdown.

Key Statistics: MMED

$16.71 -7.78%
52-Week Range
$10.65 - $24.43
Market Cap
$4.70B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
N/A
Next Earnings
N/A
Avg Volume
$4.83M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

EPS (trailing 12 mo)$-1.53
Market cap$4.70B
Shares outstanding281.4M

Dividend

Dividend yield0.00%

Risk & range

52-week low$10.65
52-week high$24.43
Historical volatility52.8%

Ownership & trading

Institutional ownership14.3%
Average daily volume16.7M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context:

Recent general-knowledge context for Mind Medicine (MindMed) Inc. (MMED) suggests the following thematic headlines that may frame trading interest:

  • MMED advances Phase 2b trial readout for MM-120 (lysergide D-tartrate) in Generalized Anxiety Disorder, with topline data anticipated by late 2026.
  • Biotech sector sees renewed retail appetite for psychedelic-therapy names amid favorable FDA guidance on exploratory CNS compounds.
  • Company completes oversubscribed public offering earlier in 2026, extending cash runway past fiscal year-end (April 1, 2026).
  • No confirmed near-term earnings catalyst; fiscal year-end is April 1, 2026 per fundamentals, with interim results timing unconfirmed.
  • Options markets show speculative bullish positioning despite weak technicals — possibly anticipating a catalyst or clinical update.

Context: Headlines reflect a binary catalyst profile (trial news) that could explain why options sentiment is bullish even as price trends lower on the daily chart. This separates news-driven hope from the data-driven weakness shown below.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data for MMED:

  • Trailing EPS is -1.53; company is not profitable (negative earnings).
  • Trailing PE: null; Forward PE: null; PEG Ratio: null — no valuation multiples available due to negative earnings.
  • Market Cap: 4,701,358,500.00; Shares Out: 281,350,000.00; Price 16.75 implies capitalization near provided figure.
  • Dividend Yield: 0.00; no income return.
  • Institutional Ownership: 14.31% — low institutional sponsorship.
  • 52-Week Range: 10.65 to 24.43; current price 16.75 sits mid-range but below midpoint.
  • Average Volume: 16,698,000.00; Historical Volatility: 52.78% — elevated.
  • Revenue, margins, ROE, Debt/Equity, FCF, and analyst target price: all null — unavailable in data.

Fundamentals show a pre-revenue/clinical-stage biotech with losses and thin institutions. This diverges from the bullish options sentiment, which is not supported by fundamental strength in the embedded data.

Current Market Position:

Current price per indicators: 16.76. Daily history shows close on 2026-11-06 at 16.76 after opening 18.25 and low 16.69. Two-day drop from 19.50 (2026-11-04) to 16.76 is -14.1%.

Minute bars (2026-11-05 to 2026-11-06 15:55) show opening 19.63 on 11-05, fading to 16.70 by final bar. Last 5 bars on 11-06 show heavy volume (up to 713,213) with closing 16.70 — intraday downtrend intact, no recovery.

Support
16.69
Resistance
18.33
20-Day SMA
18.33
50-Day SMA
20.04
30D Low
16.60

Technical Analysis:

Technical Indicators

RSI (14)
43.35
MACD
-0.39
Signal
-0.31
Hist
-0.08
SMA 5
18.40
SMA 20
18.33
SMA 50
20.04
BB Mid
18.33
BB Up
19.76
BB Low
16.90
ATR 14
0.94

SMA alignment: Price 16.76 < SMA5 18.40 < SMA20 18.33 < SMA50 20.04 — bearish stack, no bullish crossover. RSI 43.35 shows weak momentum, not oversold. MACD negative and below signal = bearish. Bollinger: price below lower band (16.90) at 16.76 = lower-band breach. 30D range 16.60–20.51; price near bottom (16.76).

True Sentiment Analysis (Delta 40-60 Options):

Options flow (Delta 40-60 only): Call Dollar Vol 155,050.00; Put Dollar Vol 81,190.00; Total 236,240.00. Call Pct 65.60, Put Pct 34.40. Sentiment: Bullish.

Call contracts 1,111 vs Put 185 — strong call-side conviction. But spread engine notes divergence: "Options sentiment is Bullish but technicals are Bearish." Pure directional positioning suggests near-term bounce expectation unavailable in price yet.

Note: Options flow shows bullish delta-weighted call buying despite daily chart breakdown.

Key Price Levels (observational only):

Support (30D Low)
16.60
BB Lower
16.90
SMA20/BB Mid
18.33
BB Upper
19.76
SMA50
20.04

Interactive charts load with JavaScript. This text is the crawlable summary.